Next Article in Journal
Clinician–Patient Communication: Evidence-Based Recommendations to Guide Practice in Cancer
Previous Article in Journal
Bogarting that Joint Might Decrease Oral hpv among Cannabis Users
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Article

Relative Dose Intensity Delivered to Patients with Early Breast Cancer: Canadian Experience

London Regional Cancer Program, 790 Commissioners Road East, London, ON N6A 4L6, Canada
*
Author to whom correspondence should be addressed.
Received: 3 September 2009 / Revised: 9 October 2009 / Accepted: 11 November 2009 / Published: 1 December 2009
Adjuvant chemotherapy for early breast cancer improves disease-free and overall survival in pre- and postmenopausal women. The importance of maintaining relative dose intensity (rdi) is well-known; however, little information is available from routine clinical practice regarding how well dose intensity is maintained with modern chemotherapy regimens. In a retrospective review of patients undergoing chemotherapy for early breast cancer at a single institution in Canada from January 2006 to November 2007, a total of 263 patients received one of the following regimens: (1) ac-t [doxorubicin (Adriamycin: Pharmacia, Kalamazoo, MI, U.S.A.)–cyclophosphamide, paclitaxel (Taxol: Bristol–Myers Squibb, Princeton, NJ, U.S.A.)]; (2) fec-100 (5-fluorouracil–epirubicin–cyclophosphamide); (3) fec-d (5-fluorouracil–epirubicin–cyclophosphamide, docetaxel). Overall, only 14.4% of patients had a rdi less than 85%. Dose delay or reduction (or both) occurred in 46%, 37%, and 20% of patients receiving fec-100, ac-t, and fec-d respectively. Optimal rdi was delivered to 96%, 95%, and 70.7% of patients for ac-t, fec-d and fec-100 regimens respectively. Patients over 65 years of age accounted for 14% of the total cohort and were more likely to receive a suboptimal rdi than were patients younger than 65 years of age (35% vs. 6.6%). Optimal chemotherapy rdi (>85%) for early breast cancer can be achieved at an academic cancer centre. This goal is less often accomplished in elderly patients, and thus a proactive approach is required for managing toxicity in that population.
Keywords: early breast cancer; adjuvant chemotherapy; relative dose intensity early breast cancer; adjuvant chemotherapy; relative dose intensity
MDPI and ACS Style

Raza, S.; Welch, S.; Younus, J. Relative Dose Intensity Delivered to Patients with Early Breast Cancer: Canadian Experience. Curr. Oncol. 2009, 16, 8-12. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v16i6.311

AMA Style

Raza S, Welch S, Younus J. Relative Dose Intensity Delivered to Patients with Early Breast Cancer: Canadian Experience. Current Oncology. 2009; 16(6):8-12. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v16i6.311

Chicago/Turabian Style

Raza, S., S. Welch, and J. Younus. 2009. "Relative Dose Intensity Delivered to Patients with Early Breast Cancer: Canadian Experience" Current Oncology 16, no. 6: 8-12. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v16i6.311

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop